StockNow
Calendar
Log in
Politics

ImmunityBio (IBRX) receives first-ever approval for Anktiva in BCG-unresponsive high-grade papillary-only bladder cancer

StockNow breaking-news AI analysis

The headline reports approval, but provides no supporting details; a later Stocktwits report says an FDA decision on a related papillary-tumor indication was still expected by January 6, 2027.

1 stocks
IBRXImmunityBio, Inc. Common Stock$9.93Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Economy

US CPI (Sep MM) 0.6% vs. Exp. 0.6% (Prev. 0.4%)

U.S. Economy

CPI Core Goods & Services (m/m SA, y/y NSA) + Supercore (Core Services ex-Rent+OER):

U.S. Economy

US Core CPI (Sep MM) 0.3% vs. Exp. 0.2% (Prev. 0.3%)